Granted Patent B2

US 12,698,481 · App. 17/818,038 · Granted Aug 4, 2026

Inventors: Baolong Zhu (San Diego, CA); Andreas W. Schirmer (San Diego, CA); Cindy Chang (San Diego, CA)

Assignee: Genomatica, Inc.

C12N9/0077C12P7/6409

Abstract

Claims (42)

1 . A CYP153A-reductase hybrid fusion polypeptide variant, comprising at least 95% sequence identity to SEQ ID NO: 6 and comprising at least one mutation at an amino acid position corresponding to amino acid position 9, 10, 12, 13, 14, 28, 56, 61, 111, 119, 140, 162, 164, 204, 244, 254, 273, 302, 327, 413, 477, 480, 481, 527, 544, 546, 557, 567, 591, 648, 649, 703, 706, 707, 708, 709, 710, 719, 720, 736, 741, 745, 747, 749, 757, 770, 771, and 784 of SEQ ID NO:6, wherein said CYP153A-reductase hybrid fusion polypeptide variant catalyzes the conversion of a fatty acid or derivative thereof to an ω-hydroxy fatty acid or derivative thereof.

2 . The CYP153A-reductase hybrid fusion polypeptide variant of claim 1 , comprising a mutation corresponding to D9N, D9K, D10Y, Q12T, Q12W, Q12R, S13K, R14F, Q28M, Q28T, P56Q, N61L, F111A, K119R, S140N, V162C, A164N, G204V, A244R, R254G, P273M, T302M, P327D, Y413R, P477G, I480G, G481I, D527E, D544N, P546G, E557W, E557R, E567S, E591Q, V648L, S649I, L703G, L706E, L706S, L706H, D707E, P708S, D709L, V710R, V710Q, V710C, R719W, D720V, A736V, N741G, P745R, P745K, D747N, E749L, E749M, E757A, T770G, V771F, or M784I.

3 . A recombinant host cell, comprising the CYP153A-reductase hybrid fusion polypeptide variant of claim 1 .

4 . The recombinant host cell of claim 3 , wherein:

the recombinant host cell produces an ω-hydroxy fatty acid or a derivative thereof;

the ω-hydroxy fatty acid or derivative thereof is one or more of a saturated or unsaturated C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20 ω-hydroxy fatty acid or derivative thereof; and

the ω-hydroxy fatty acid or derivative thereof is produced intracellularly or extracellularly.

5 . The recombinant host cell of claim 3 , wherein:

the recombinant host cell further expresses a thioesterase, or an ester synthase, or a combination thereof; and

the recombinant host cell produces an ω-hydroxy fatty acid, or an ω-hydroxy fatty acid derivative that is an ω-hydroxy fatty acid ester, or a combination thereof.

6 . The recombinant host cell of claim 3 , further expressing:

(a) an alcohol dehydrogenase or an alcohol oxidase, wherein the recombinant host cell produces an ω-hydroxy fatty acid derivative that is an ω-oxo fatty acid, an ω-oxo fatty acid ester, or a combination thereof;

(b) an alcohol dehydrogenase or an alcohol oxidase, and an aldehyde dehydrogenase or an aldehyde oxidase, wherein the recombinant host cell produces an ω-hydroxy fatty acid derivative that is an α,ω-diacid, ω-carboxy fatty acid ester, or a combination thereof;

(c) an alcohol dehydrogenase or an alcohol oxidase, an aldehyde dehydrogenase or an aldehyde oxidase, and an acyl-CoA ligase or an acyl-CoA transferase, wherein the recombinant host cell produces an ω-hydroxy fatty acid derivative that is an α,ω-diester;

(d) an alcohol dehydrogenase or an alcohol oxidase, and an aminotransferase or an amine dehydrogenase, wherein the recombinant host cell produces an ω-hydroxy fatty acid derivative that is an ω-amino fatty acid, an ω-amino fatty acid ester, or a combination thereof;

(e) an alcohol dehydrogenase and a carboxylic acid reductase, wherein the recombinant host cell produces an ω-hydroxy fatty acid derivative that is an α,ω-diol; or

(f) an acyl-ACP reductase and an alcohol dehydrogenase, wherein the recombinant host cell produces an ω-hydroxy fatty acid derivative that is an α,ω-diol.

7 . The recombinant host cell of claim 6 , further expressing a thioesterase, or an ester synthase, or a combination thereof.

8 . A recombinant host cell, expressing the CYP153A-reductase hybrid fusion polypeptide variant of claim 2 .

9 . A cell culture, comprising the recombinant host cell of claim 3 .

10 . The cell culture of claim 9 , wherein:

the cell culture produces an ω-hydroxy fatty acid or a derivative thereof; and

the ω-hydroxy fatty acid or derivative thereof is one or more of a saturated or unsaturated C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20 ω-hydroxy fatty acid or derivative thereof.

11 . A cell culture, comprising the recombinant host cell of claim 8 .

12 . A method for producing an ω-hydroxy fatty acid or a derivative thereof, the method comprising:

(i) culturing the recombinant host cell of claim 3 in a medium comprising a carbon source; and

(ii) optionally harvesting the ω-hydroxy fatty acid or derivative thereof.

13 . The method of claim 12 , wherein the ω-hydroxy fatty acid or derivative thereof is one or more of a saturated or unsaturated C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20 ω-hydroxy fatty acid or derivative thereof.

14 . The method of claim 12 , wherein the recombinant host cell produces an ω-hydroxy fatty acid or derivative thereof at a titer that is at least 10% greater, at least 15% greater, at least 20% greater, at least 25% greater, or at least 30% greater than the titer of an ω-hydroxy fatty acid or derivative thereof produced by a host cell comprising a CYP153A-reductase hybrid fusion polypeptide of SEQ ID NO:6.

15 . The method of claim 13 , wherein the ω-hydroxy fatty acid or derivative thereof is an ω-hydroxy fatty acid, an ω-hydroxy fatty acid ester, an ω-oxo fatty acid, an ω-oxo fatty acid ester, an α,ω-diacid, an ω-carboxy fatty acid ester, an α,ω-diester, ω-amino fatty acid, an ω-amino fatty acid ester, an α,ω-diol, or a combination thereof.

16 . A method of producing an ω-hydroxy fatty acid or a derivative thereof, the method comprising:

(i) culturing the recombinant host cell of claim 8 in the presence of a carbon source; and

(ii) optionally harvesting the ω-hydroxy fatty acid or derivative thereof.

17 . The method of claim 16 , wherein the ω-hydroxy fatty acid or derivative thereof is one or more of a saturated or unsaturated C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20 ω-hydroxy fatty acid or derivative thereof.

18 . The method of claim 17 , wherein the ω-hydroxy fatty acid or derivative thereof is an ω-hydroxy fatty acid, an ω-hydroxy fatty acid ester, an ω-oxo fatty acid, an ω-oxo fatty acid ester, an α,ω-diacid, an ω-carboxy fatty acid ester, an α,ω-diester, an ω-amino fatty acid, an ω-amino fatty acid ester, an α,ω-diol, or a combination thereof.

19 . A method of producing an ω-hydroxy fatty acid or a derivative thereof, the method comprising:

(i) culturing the recombinant host cell of claim 6 in the presence of a carbon source; and

(ii) optionally harvesting the ω-hydroxy fatty acid or derivative thereof.

20 . The method of claim 19 , wherein:

the ω-hydroxy fatty acid or derivative thereof is one or more of a saturated or unsaturated C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20 w-hydroxy fatty acid or derivative thereof; and

the ω-hydroxy fatty acid or derivative thereof is an ω-hydroxy fatty acid, an ω-hydroxy fatty acid ester, an ω-oxo fatty acid, an ω-oxo fatty acid ester, an α,ω-diacid, an ω-carboxy fatty acid ester, an α,ω-diester, an ω-amino fatty acid, an ω-amino fatty acid ester, an α,ω-diol, or a combination thereof.

21 . The CYP153A-reductase hybrid fusion polypeptide variant of claim 1 , further comprising one or more mutations corresponding to I11L, P149G, V154G, S157R, A231W, A231Y, A231V, S233L, S233V, E271D, or N407G.

Assignments (5)

Continuity (4)

References Cited (224)